Patent EP0573137A2 successfully refreshed from Google Patents.
EP0573137A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Methods and devices for facilitated non-invasive oxygen monitoring
Assignee: Alza Corp
•
Filing: 1993-02-19
•
Granted: —
•
Expires: 2013-02-19
Abstract
Abstract The present invention is directed to a sensor system for use with a blood characteristic measurement device such as a pulse oximeter, on areas of the body having low normal cutaneous blood flow and for monitoring a blood characteristic such as oxygen saturation and pulse rate of patients, preferably over an extended period of time. The sensor system includes (a) a transdermal device containing a blood perfusion-enhancing agent that is administered in a controlled amount to the skin of a human patient and (b) a skin surface sensor.
Inventors
- 👤 Jessica A. Warring
- 👤 Su Il Yum
- 👤 David B. Swedlow
- 👤 Lina T. Taskovich
- 👤 Michel J.N. Cormier
- 👤 Albert Ollerdessen
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 11:22
CPC Classifications
A; A61; A61B; A61B5/00; A61B5/68; A61B5/6801; A61B5/683; A61B5/6832; A61B5/6833; A61B5/02; A61B5/024; A61B5/02416; A61B5/02427; A61B5/02433; A61B5/145; A61B5/1455; A61B5/14551; A61B5/14552
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
82 words
A transdermal delivery device for facilitating the non-invasive monitoring of a characteristic of a patient's blood, wherein the device consists essentially of: (a) a backing member that is substantially impermeable to a perfusion-enhancing agent; (b) a first adhesive layer adjacent to the skin-distal surface of the backing member; (c) a reservoir adjacent to the skin-proximal surface of the backing member, the reservoir comprising a perfusion-enhancing amount of a perfusion-enhancing agent; (d) a rate-controlling membrane adjacent to the skin-proximal surface of the reservoir.
Claim 2
Dependent Claim
82 words
A transdermal delivery device for facilitating the non-invasive monitoring of a characteristic of a patient's blood, wherein the device consists essentially of: (a) a backing member that is substantially impermeable to a perfusion-enhancing agent; (b) a first adhesive layer adjacent to the skin-distal surface of the backing member; (c) a reservoir adjacent to the skin-proximal surface of the backing member, the reservoir comprising a perfusion-enhancing amount of a perfusion-enhancing agent; (d) a rate-controlling membrane adjacent to the skin-proximal surface of the reservoir.
Claim 3
Dependent Claim
22 words
A device according to claim 1 which further comprises a second adhesive layer adjacent to the skin-proximal surface of the rate-controlling membrane.
Claim 4
Dependent Claim
14 words
A device according to claim 1 or claim 2 wherein the device is opaque.
Claim 5
Independent Claim
14 words
A device according to any preceding claim wherein the perfusion-enhancing agent is a vasodilator.
Claim 6
Dependent Claim
21 words
A device according to claim 4 wherein the vasodilator is selected from nicotinic acid and lower alkyl esters of nicotinic acid.
Claim 7
Independent Claim
14 words
A device according to any preceding claim wherein the perfusion-enhancing agent is methyl nicotinate.
Claim 8
Independent Claim
19 words
A device according to any preceding claim wherein the device further comprises an emitter window and a detector window.
Claim 9
Independent Claim
39 words
A device according to any preceding claim wherein the perfusion-enhancing agent is methyl nicotinate and the device further comprises a second adhesive layer adjacent to the skin-proximal surface of the rate-controlling membrane, an emitter window and a detector window.
Claim 10
Independent Claim
14 words
A device according to any preceding claim wherein the perfusion-enhancing agent is a counter-irritant.
Claim 11
Independent Claim
38 words
A device as claimed in any preceding claim whereby a perfusion-enhancing agent is delivered to a patient at a substantially constant rate over an extended period of time to obtain a localized increase of the cutaneous blood flow.
Claim 12
Dependent Claim
19 words
A device according to claim 10 wherein the extended period of time is from 8 hours to 3 days.
Claim 13
Independent Claim
48 words
A device as claimed in any preceding claim in combination with a sensor housing; a light source disposed in the sensor housing; a photodetector disposed in the sensor housing; and means for mating the sensor housing with said device, thereby permitting the non-invasive monitoring of a patients blood.
Claim 14
Dependent Claim
39 words
A device according to claim 12 wherein the housing comprises an active face and a cavity containing the light source and the photodetector, and the means for mating comprises a planar surface covering and extending laterally beyond the cavity.
Claim 15
Independent Claim
27 words
A device according to claims 12 or 13 wherein the means for mating further comprises means for reducing optical shunting between the light source and the photodetector.
Claim 16
Independent Claim
34 words
A device according to any one of claims 12 to 14 wherein the means for mating further comprises means for reducing optical shunting between the light source and the photodetector through a transdermal device.
Claim 17
Dependent Claim
32 words
A sensor according to any one of claims 12 to 15 wherein the means for reducing optical shunting comprises a ridge disposed on the housing between the light source and the photodetector.
Claim 18
Independent Claim
29 words
A device according to any one of claims 12 to 16 wherein the means for reducing optical shunting comprises a ridge disposed on the housing surrounding the light source.
Claim 19
Independent Claim
29 words
A device according to any one of claims 12 to 17 wherein the means for reducing optical shunting comprises a ridge disposed on the housing surrounding the light photodetector.
Claim 20
Independent Claim
41 words
A device according to any one of claims 12 to 18 wherein the means for mating the sensor housing with the transdermal device comprises a second adhesive layer in the transdermal device adjacent to the skin-distal surface of the backing member.
Claim 21
Independent Claim
72 words
A device according to any one of claims 12 to 19 wherein the sensor housing comprises an active face, a cavity containing the light source and the photodetector and a planar surface covering and extending laterally beyond the cavity, and the means for mating comprises a second adhesive layer in the transdermal device adjacent to the skin-distal surface of the backing member and adjacent to the planar surface of the sensor housing.
Claim 22
Independent Claim
40 words
A device according to any one of claims 12 to 20 which further comprises a first window through the transdermal delivery device adjacent to the light source and a second window through the transdermal delivery device adjacent to the photodetector.
Claim 23
Dependent Claim
26 words
A device according to claim 21 which further comprises means for reducing optical shunting between the light source and the photodetector through the transdermal delivery device.
Claim 24
Dependent Claim
32 words
A device according to claim 22 wherein the means for reducing optical shunting comprises a ridge surrounding the light source and extending substantially through the first window of the transdermal delivery device.
Claim 25
Independent Claim
36 words
A device according to any one of claims 12 to 23 wherein the means for reducing optical shunting comprises a ridge surrounding the photodetector and extending substantially through the second window of the transdermal delivery device.
Claim 26
Independent Claim
84 words
A method for non-invasively monitoring a characteristic of the blood of a patient, the method comprising the following steps: applying a transdermal delivery device to an electro-optical sensor, the transdermal delivery device comprising a backing member that is substantially impermeable to a perfusion-enhancing agent, a reservoir comprising a perfusion-enhancing amount of a perfusion-enhancing agent, and a rate-controlling membrane; placing the transdermal delivery device and sensor on a predetermined site on the patient's skin; and monitoring a characteristic of the patient's blood with the sensor.
Claim 27
Independent Claim
84 words
A method for non-invasively monitoring a characteristic of the blood of a patient, the method comprising the following steps: applying a transdermal delivery device to an electro-optical sensor, the transdermal delivery device comprising a backing member that is substantially impermeable to a perfusion-enhancing agent, a reservoir comprising a perfusion-enhancing amount of a perfusion-enhancing agent, and a rate-controlling membrane; placing the transdermal delivery device and sensor on a predetermined site on the patient's skin; and monitoring a characteristic of the patient's blood with the sensor.
Claim 28
Independent Claim
90 words
A method for non-invasively monitoring a characteristic of the blood of a patient, the method comprising the following steps: applying a first surface of a transdermal delivery device to a predetermined site on the patient's skin, the transdermal delivery device comprising a backing member that is substantially impermeable to a perfusion-enhancing agent, a reservoir comprising a perfusion-enhancing amount of a perfusion-enhancing agent, and a rate-controlling membrane; placing an electro-optical sensor on a second surface of the transdermal delivery device; and monitoring a characteristic of the patient's blood with the sensor.
Claim 29
Independent Claim
90 words
A method for non-invasively monitoring a characteristic of the blood of a patient, the method comprising the following steps: applying a first surface of a transdermal delivery device to a predetermined site on the patient's skin, the transdermal delivery device comprising a backing member that is substantially impermeable to a perfusion-enhancing agent, a reservoir comprising a perfusion-enhancing amount of a perfusion-enhancing agent, and a rate-controlling membrane; placing an electro-optical sensor on a second surface of the transdermal delivery device; and monitoring a characteristic of the patient's blood with the sensor.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.